Browse by author
Lookup NU author(s): Professor Alan Calvert
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Twenty patients with locally advanced or metastatic breast cancer were treated with four cycles of ifosfamide/mesna 5 g m(-2) and epirubicin 60 mg m(-2) every 14 days with granulocyte colony-stimulating factor (G-CSF, Filgrastim). Complete remission occurred in six out of the 20 patients (30%, 95% confidence interval 12-54%) and there were 12 partial responders (60%, 95% confidence interval 37-81%), thus giving an overall response rate of 90% (95% confidence interval 63-97%). Two patients had progressive disease. The median duration of response for those patients with metastatic disease was 7.3 (1.3-20.1 +) months. The median survival time for these patients was 15 (5.3-27.9 +) months. Of the four patients treated with locally advanced disease three achieved a complete clinical response and one a partial response. Three out of four of these patients subsequently underwent a mastectomy, and in one of these no viable tumour was seen. Our conclusion is that this regimen is excellent palliation for metastatic disease and possibly useful neoadjuvant treatment.
Author(s): Lind, M. J., Gumbrell, L., Cantwell, B. M. J., Millward, M. J., Simmonds, D., Proctor, M., Chapman, F., McCann, E., Middleton, I., Calvert, A. H.
Publication type: Article
Publication status: Published
Journal: British Journal of Cancer
Year: 1995
Volume: 71
Issue: 3
Pages: 610-613
Print publication date: 01/03/1995
ISSN (print):
ISSN (electronic):
PubMed id: 7533518
